The 15 most promising biotech companies

FierceBiotech 2009 Fierce 15 winner

Every year our sister publication FierceBiotech publishes the Fierce 15, a list of the most promising private biotech companies. This year's report is made up of drug developers who have vision, good science and solid management that have helped them not only suvive but excel in the face of economic challenges. These biotechs boast ground-breaking technologies that are redefining the biotech industry amidst adverse market conditions. Some of the winning innovations include a potentially new generation of anti-bacterials, advancements in oncology treatments, and cutting-edge developments in the stem cell field.

Click here to see the 2009 Fierce 15 winners. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.